S
3.40
0.09 (2.72%)
| Previous Close | 3.31 |
| Open | 3.36 |
| Volume | 3,001,575 |
| Avg. Volume (3M) | 1,227,495 |
| Market Cap | 587,645,760 |
| Price / Book | 5.21 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2025 |
| Diluted EPS (TTM) | -0.490 |
| Total Debt/Equity (MRQ) | 20.08% |
| Current Ratio (MRQ) | 14.91 |
| Operating Cash Flow (TTM) | -95.63 M |
| Levered Free Cash Flow (TTM) | -56.02 M |
| Return on Assets (TTM) | -38.97% |
| Return on Equity (TTM) | -75.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Savara, Inc. | Bullish | Bearish |
AIStockmoo Score
3.4
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 3.38 |
|
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 5.38% |
| % Held by Institutions | 98.53% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 11.00 (Guggenheim, 223.53%) | Buy |
| Median | 8.00 (135.29%) | |
| Low | 8.00 (HC Wainwright & Co., 135.29%) | Buy |
| 8.00 (Oppenheimer, 135.29%) | Buy | |
| Average | 9.00 (164.71%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 3.70 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 09 Sep 2025 | 11.00 (223.53%) | Buy | 3.82 |
| Oppenheimer | 08 Sep 2025 | 8.00 (135.29%) | Buy | 3.85 |
| 15 Aug 2025 | 6.00 (76.47%) | Buy | 3.04 | |
| HC Wainwright & Co. | 03 Sep 2025 | 8.00 (135.29%) | Buy | 3.42 |
| 15 Aug 2025 | 5.00 (47.06%) | Buy | 3.04 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Sep 2025 | Announcement | Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis |
| 26 Aug 2025 | Announcement | Savara Announces Participation in Upcoming Investor Healthcare Conferences |
| 20 Aug 2025 | Announcement | New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) |
| 13 Aug 2025 | Announcement | Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update |
| 18 Jul 2025 | Announcement | Savara Announces New Employment Inducement Grant |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |